US Patent

US10869869 — Method of adjuvant cancer treatment

Method of Use · Assigned to Novartis AG · Expires 2033-08-30 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of providing adjuvant cancer treatment by administering dabrafenib and trametinib to a human patient.

USPTO Abstract

The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3184`	—	trametinib-dimethyl-sulfoxide
`U-3184`	—	trametinib-dimethyl-sulfoxide
`U-3184`	—	trametinib-dimethyl-sulfoxide
`U-3185`	—	dabrafenib-mesylate
`U-3185`	—	dabrafenib-mesylate

Patent Metadata

Patent number: US10869869
Jurisdiction: US
Classification: Method of Use
Expires: 2033-08-30
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.